Related Experiment Videos
Aberrant immunophenotypes detected by flow cytometry in acute lymphoblastic leukemia
J A García Vela1, M C Monteserin, I Delgado
1Department of Hematology, Hospital Universitario de Getafe, Madrid, Spain. javela@ran.es
Leukemia & Lymphoma
|February 16, 2000
Summary
Detecting minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) is feasible using aberrant phenotypes. Most ALL patients exhibit these phenotypic aberrations at diagnosis, aiding in patient follow-up during remission.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Minimal residual disease (MRD) detection is crucial for acute lymphoblastic leukemia (ALL) patient management.
- Phenotypic detection of MRD relies on identifying aberrant blast cell phenotypes.
Purpose of the Study:
- To determine the feasibility of phenotypic MRD detection in ALL patients.
- To analyze the proportion of ALL patients with aberrant phenotypes at diagnosis.
Main Methods:
- Prospective investigation of blast cell phenotype in 25 ALL patients at diagnosis.
- Utilized multiparametric flow cytometry with a large panel of monoclonal antibodies.
- Classified patients based on FAB classification and immunophenotype (B-lineage vs. T-ALL).
Main Results:
- 92% of ALL patients (23/25) displayed phenotypic aberrations at diagnosis.
- 17/17 B-lineage ALL and all 8 T-ALL cases showed aberrations.
- 76% of patients had two or more aberrant phenotypes, including lineage infidelity, asynchronous expression, overexpression, and ectopic phenotypes.
Conclusions:
- Most ALL patients exhibit aberrant phenotypes at diagnosis when analyzed with extensive antibody panels.
- The frequent co-occurrence of multiple aberrant phenotypes supports their utility for MRD detection.
- Immunological methods based on aberrant phenotypes can significantly aid in monitoring ALL patients in complete remission.